Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07904780
PHASE4

Withdrawal Versus Continued TNF Inhibitor Monotherapy Treatment in Children With Inactive Juvenile Idiopathic Arthritis

Sponsor: Oslo University Hospital

View on ClinicalTrials.gov

Summary

The goal of this clinical trial is to learn whether children and adolescents with juvenile idiopathic arthritis (JIA) who have had inactive disease for a long time can safely discontinue treatment with a tumour necrosis factor inhibitor (TNF-inhibitor) monotherapy. The trial compares TNFi withdrawal with continued treatment at a stable dose. The main question it aims to answer is whether TNF-inhibitor withdrawal increases the risk of disease flare during 12 months of follow-up compared with continued treatment. The trial will also assess time to flare, time to regain inactive disease after a flare, changes in disease activity, and the overall safety of both treatment strategies during the same period. Ninety patients aged 2 to 17 years with non-systemic JIA will take part. All of them will have had inactive disease for at least 12 months while on TNF-inhibitor monotherapy with adalimumab, etanercept or golimumab. Participants will be randomly assigned either to continue their current TNF-inhibitor treatment at a stable dose or to TNF-inhibitor withdrawal. They will be followed for 12 months at three hospitals in Norway, with regular visits where disease activity is assessed through joint examination and the Juvenile Arthritis Disease Activity Score (JADAS-27), and where side effects and other health problems are recorded. A flare is defined as a clinically significant increase in disease activity together with at least one active joint, or as agreement between the treating physician and the participant or parents that a flare has occurred.

Official title: Treatment Strategies for Juvenile Idiopathic Arthritis Patients With Sustained Inactive Disease: A Phase 4, Multicentre, Randomised Trial Comparing Maintenance Versus Tapered TNF Alpha Inhibitor Monotherapy - the Treat-JIA Trial

Key Details

Gender

All

Age Range

2 Years - 17 Years

Study Type

INTERVENTIONAL

Enrollment

90

Start Date

2026-11-11

Completion Date

2030-11-11

Last Updated

2026-10-29

Healthy Volunteers

No

Interventions

DRUG

Adalimumab

Gradual withdrawal of the medication

DRUG

Etanercept

Gradual withdrawal of the medication

DRUG

Golimumab

Gradual withdrawal of the medication

DRUG

Adalimumab

Continued stable adalimumab monotherapy

DRUG

Etanercept

Continued stable etanercept monotherapy

DRUG

Golimumab

Continued stable golimumab monotherapy

Locations (3)

Drammen Hospital

Drammen, Norway

Hospital of Southern Norway Hospital Trust

Kristiansand, Norway

Oslo University Hospital

Oslo, Norway